Vicore Pharma Holding AB (publ) (VICO.ST)
- Previous Close
16.68 - Open
17.00 - Bid 16.74 x --
- Ask 16.86 x --
- Day's Range
16.70 - 17.00 - 52 Week Range
12.36 - 26.90 - Volume
4,025 - Avg. Volume
208,373 - Market Cap (intraday)
1.886B - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-3.22 - Earnings Date May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
56.50
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. Vicore Pharma Holding AB (publ) has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
www.vicorepharma.comRecent News: VICO.ST
Performance Overview: VICO.ST
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VICO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VICO.ST
Valuation Measures
Market Cap
1.86B
Enterprise Value
1.60B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.09
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.21
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.99%
Return on Equity (ttm)
-83.53%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-310.94M
Diluted EPS (ttm)
-3.22
Balance Sheet and Cash Flow
Total Cash (mrq)
482.77M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-200.41M
Research Analysis: VICO.ST
Company Insights: VICO.ST
VICO.ST does not have Company Insights